Highlights

  • Second quarter net loss was approximately USD 6.6 million against USD 6.3 million.
  • Cash, cash equivalents and marketable securities were approximately USD 24.9 million.
  • Two June 2026 equity financings raised gross proceeds of about USD 20.5 million.
  • Management expects cash to fund operations through the third quarter of 2027.

CervoMed Inc. (NASDAQ:CRVO) shares were trading near their all-time low at USD 1.37 on November 6, 2026, down 5.52% on the day. The company reported a second quarter net loss of approximately USD 6.6 million and cash, cash equivalents and marketable securities of approximately USD 24.9 million.

CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead candidate, neflamapimod, is an oral small molecule that inhibits the Alpha isoform of p38 MAP kinase.

Financial Results

Net loss was approximately USD 6.6 million against USD 6.3 million, an aggregate increase of USD 0.3 million. The company reported no grant Revenue against approximately USD 1.8 million a year earlier. The Phase 2b RewinD-LB trial finished in mid-2025, and no further funding is available or expected under the USD 21.3 million National Institute on Aging grant.

Research and development expenses were approximately USD 4.3 million against USD 5.1 million. General and administrative expenses were approximately USD 2.4 million against USD 3.3 million. Total operating expenses decreased by USD 1.7 million.

Cash and Funding

Cash, cash equivalents and marketable securities were approximately USD 24.9 million at June 30, 2026, against USD 20.9 million at December 31, 2025. The company completed two equity financings in June 2026 for aggregate gross proceeds of approximately USD 20.5 million.

Based on its current operating plan, the company believes the resources on hand will fund planned operating expenses and Capital Expenditure requirements through the third quarter of 2027.

Dementia with Lewy Bodies Program

In June 2026, the company announced its intent to establish a strategic Partnership to advance neflamapimod into a Phase 3 trial in dementia with Lewy bodies. The chief executive said the primary strategic objective is to secure a partner.

In August 2026, neflamapimod received an Innovation Passport designation under the United Kingdom's ILAP pathway. The company also received a notice of allowance in June 2026 for a Patent covering use of neflamapimod into 2042 in patients without substantial Alzheimer's disease-like tau pathology.

New analyses at the Alzheimer's Association International Conference supported the 50 mg three-times-daily dose for the planned Phase 3 trial. Company analyses of the Phase 2b RewinD-LB trial cite a higher-than-targeted share of patients with Alzheimer's co-pathology and a drug batch that underachieved target plasma concentrations.

Other Programs

Initial 12-week biomarker data from the Phase 2a trial in nonfluent variant primary progressive aphasia are due in October 2026 at an international conference, with fuller data in November 2026. The company expects to dose the first patient in its EXPERTS-ALS trial by the end of 2026 and to report topline data from its Phase 2a RESTORE stroke trial in the second half of 2026.